Close Menu

NEW YORK (360Dx) – Exosome Diagnostics said this week that it has expanded the coverage of its ExoDx Prostate IntelliScore (EPI) cancer test to an additional 82 million covered lives in the US, bringing the total to about 100 million. The firm said that the additional coverage is the result of contracts to provide laboratory services and ExoDx prostate cancer testing to patients of three preferred provider organizations in the US — Three Rivers Provider Network, FedMed, and America’s Choice Provider Network.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.